Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Ziprasidone is an atypical antipsychotic that is approved by the US Food and Drug Administration for the treatment of schizophrenia, acute mania, and mixed states associated with bipolar disorder. Food influences the bioavailability of ziprasidone, and guidelines advise taking ziprasidone with meals containing approximately 500 kilocalories. Failure to do so can result in a decrease in intestinal absorption by 50% and inconsistent efficacy.
Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
Please sign in or purchase this PDF for $40.00.